Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Sep 3, 2024
- Accession no.
- 0001447362-24-000139
- Filed
- Sep 3, 2024
- Trade date
- Aug 29-30, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $133.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 29, 2024 | Common Stock | SSaleDisposed | −1,334 | $30.08F2 | −$40,126.72 | 100,609 | Direct | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −688 | $30.08F2 | −$20,695.04 | 81,221 | Indirect | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −688 | $30.08F2 | −$20,695.04 | 70,118 | Indirect | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −216 | $30.08F2 | −$6,497.28 | 8,126 | Indirect | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −218 | $30.08F2 | −$6,557.44 | 8,126 | Indirect | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −218 | $30.08F2 | −$6,557.44 | 8,126 | Indirect | |
| Aug 29, 2024 | Common Stock | SSaleDisposed | −218 | $30.08F2 | −$6,557.44 | 8,126 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −322 | $30.10F9 | −$9,692.2 | 100,287 | Direct | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −165 | $30.10F9 | −$4,966.5 | 81,056 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −165 | $30.10F9 | −$4,966.5 | 69,953 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −50 | $30.10F9 | −$1,505 | 8,076 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −53 | $30.10F9 | −$1,595.3 | 8,073 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −53 | $30.10F9 | −$1,595.3 | 8,073 | Indirect | |
| Aug 30, 2024 | Common Stock | SSaleDisposed | −53 | $30.10F9 | −$1,595.3 | 8,073 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $30.000 to $30.285, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $30.000 to $30.265, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.